Standing with the pulmonary arterial hypertension (PAH) community through COVID-19


The COVID-19 pandemic is an unprecedented health threat that is affecting the global population. People living with PAH are extremely vulnerable and may be more likely to be at high-risk of severe illness if they contract the virus.

During this time, medical routines and appointments have adapted to ensure patient safety and ease the current burden on global healthcare systems. To the physicians, nurses and carers who are on the frontline of this pandemic, we thank you for your service and increased contribution to the welfare of the global population. We remain here to support you as best we can to serve the PAH community.

If you, a family member or a friend have PAH, we understand that during this time of uncertainty you may be concerned about the availability of treatment. Please be assured that, at Actelion, we are committed to maintaining our supply chain so that the availability of treatment remains stable. We urge you to continue to stay safe by following government advice and maintaining social distancing rules. For more information or support on living with PAH during the COVID-19 pandemic, please reach out to your local patient advocacy group and/or your treating physician.

We stand with you all during this time. We are with you until PH isn’t.

 

Target diseases

Target diseases

Actelion’s products and late-stage development compounds target a number of different diseases.

Contact

Contact